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Abstract

Methicillin-Resistant Staphylococcus aureus (MRSA) has developed resistance towards a
number of antibiotics. This resistance creates a challenge when trying to treat MRSA
with a number of antibiotics. This is mainly caused by the penicillin-binding proteins 2a
(PBP2a). PBP2a have significantly less affinity for beta-lactam antibiotics compared to
the other penicillin-binding proteins (PBPs) expressed by non-resistant strains. New
treatments involving a combination of antibiotics and herbal extracts are being developed
and used to inactivate PBP2a, allowing the previous ineffective antibiotics to be more
effective.
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Current Antibiotics and Future Herbal Extract Methods to Treat Methicillin-Resistant
Staphylococcus aureus (MRSA): Focusing on Inhibition of Penicillin-Binding Protein 2a
(PBP2a)
Staphylococcus aureus is a Gram-positive bacterium discovered in the 1880s. S.
aureus is a pathogenic bacterium that causes infections as minor as those that affect the
skin to severe post-operative wound complications. During the early 1940s, before the
use of penicillin to treat S. aureus infections, these infections had a mortality rate as high
as 80%, but as soon as penicillin started being used as a treatment option in 1942, a first
resistant strain was isolated in a hospital. In 1962, a similar situation happened, where
after the introduction of penicillin derivatives as an alternative to penicillin for treatment
for S. aureus infections, resistant strains were isolated (Public Health in the 21st Century:
MRSA (Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 2010).
These resistant strains were observed in the hospitals as well as in the community, which
led to the coining of the terms Hospital Acquired-MRSA (HA-MRSA) and Community
Acquired-MRSA (CA-MRSA).
Currently, S. aureus is one of the major pathogens in the world. S. aureus is a
serious threat to the public health and is a major nosocomial infection since hospitals are
concentrated with people with weakened immunity (Wishart, Loughrey, McClurg,
Goldsmith, & et al., 2007; Kelley, Jousselin, Barras, Lelong, & Renzoni, 2015; Otero et
al., 2013). The high usage of implanted prosthetic biomaterials contribute to some of the
cases involving MRSA outbreaks in hospitals since such devices could be breeding
grounds for MRSA colonies (Pozzi et al., 2012). Compared to other clinically important
bacteria, MRSA distinguishes itself from the rest because the bacterium possesses a
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variety of virulence factors including the production of biofilms; MRSA is resistance to a
broad spectrum of antimicrobial drugs and can be found in both hospital and community
settings at significantly high occurrences (Public Health in the 21st Century: MRSA
(Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 2010).
Penicillin-Binding Protein (PBP)
The bacterial cell wall is an important part of the overall structure of the cell. The
cell wall is mainly composed of peptidoglycan that help the bacterium to resist
intracellular and extracellular pressures while maintaining the rigidity of the cell
(Sauvage, Kerff, Terrak, Ayala, & Charlier, 2008). This also helps give the bacterial cell
a more defined shape compared to animal cells that lack a cell wall. Likewise, penicillinbinding proteins (PBP) are responsible for the polymerization and cross-linkage of
peptidoglycans to form the bacterium cell wall (Sauvage et al., 2008). The last D-alanine
of stem pentapeptides is one of the main regions on the peptidoglycans used by PBPs
during cross-linkage. These cross-linking regions have structural similarities to penicillin
(and its derivatives) that allow some PBPs form acyl-enzymes with the penicillin,
inhibiting any cross-linking capabilities (Sauvage et al., 2008).
There are many different types of PBPs coded by different genes. Bacteria can
have as many as 6 different PBPs. PBPs are divided into two main groups: the high
molecular mass (HMM) PBPs, and the low molecular mass (LMM) PBPs (Sauvage et al.,
2008). HMM PBPs deal with polymerization of peptidoglycans and insertion of
peptidoglycans into the cell walls of pre-existing cells. LMM PBPs mainly deal with cell
remodeling activities such as cell separation, peptidoglycan maturation, and recycling
(Sauvage et al., 2008).
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Penicillin-Binding Protein 2a (PBP2a)
Penicillin-binding protein 2a (PBP2a) is an alternative structural protein
synthesized by MRSA to take over the functions of normal PBPs when subjected to stress
in the environment, such as through the addition of antibiotics. PBP2a has an extremely
lower affinity for antibiotics than the normal PBPs, which creates a serious problem when
developing new antibiotics against MRSA (Pinho, de Lencastre, & Tomasz, 2001; Pinho,
Filipe, de Lencastre, & Tomasz, 2001). PBP2a consists of an N-terminal transmembrane
anchor, a C-terminal transpeptidase domain, and a bilobal nonpenicillin-binding domain
(Figure 1). The protein is approximately 130 by 60 by 58 Å, where Å= 10-10 m (D. Lim &
Natalie, 2002). The mecA gene is responsible for encoding PBP2a (Alexander, 2003;
Ender, Berger-Bachi, & McCallum, 2009; Haghighat, Siadat, Sorkhabadi, Sepahi, &
Mahdavi, 2013; Kim et al., 2013; D. Lim & Natalie, 2002). The acquired mecA gene is
only 2.1 kilobases (kb) in length and is located on the S. aureus chromosome in the
mobile genetic element that is known as staphylococcal cassette chromosome mec
(SCCmec) (Pozzi et al., 2012). Although this element is mobile and capable of being
transferred from one bacterium to another, SCCmec still inserts itself at specific and
consistent positions on the S. aureus chromosome. (Katayama, Robinson, Enright, &
Chambers, 2005; Public Health in the 21st Century: MRSA (Methicillin Resistant
Staphylococcus aureus) Infections and Treatment, 2010).
There are currently seven identified variants of the SCCmec that differ in their
size but serve the same function of conferring antibiotics resistance to MRSA (Katayama
et al., 2005). SCCmec type 1 contains 34.3 kb; type IV contains 20.9-24.3kb; type V
contains 28 kb; type VI has 20.9 kb; and type VII has 35.9 kb. These variants confer
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Figure 1: Structure of PBP2a. Reprinted by permission from Macmillan Publishers Ltd:
[NATURE STRUCTURAL & MOLECULAR BIOLOGY] (D. Lim & Natalie, 2002),
copyright (2002).
resistance against β-lactam antibiotics only. The type II (53.0 kb) and III (66.9 kb) confer
resistance against multiple classes of antibiotics (Public Health in the 21st Century:
MRSA (Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 2010).
However, the mecA gene is not always active. The mecA gene is only active when
normal PBPs fail to function or are inhibited by antibiotics. The SCCmec also contains
other genes, mecR1 and mecI that serve as regulatory components to the mecA gene
(Ender et al., 2009; McKinney, Sharma, Craig, & Archer, 2001). These regulatory genes
have promoter regions that overlap with that of mecA. The mecR1 encodes a protein that
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senses the stress in the bacterial environment and activates the mecA gene. The mecI
gene does the opposite and is responsible for repressing the transcription of mecA when
the bacterium does not need PBP2a (Ender et al., 2009; McKinney et al., 2001).
Therefore, in order for PBP2a to be synthesized, mecR1 needs to be activated; otherwise,
mecI will suppress the gene. Some bacteria lack both mecR1 and mecI. This DNA
segment is either truncated or absent all together. In these bacteria, the regulation of
mecA is controlled by the blaR1/blaI genes. These genes work in a similar fashion to
mecR1/mecI. The blaR1/blaI genes regulate the transcription of blaZ, which codes for βlactamases, enzymes that degrade β-lactam antibiotics such as penicillin (Ender et al.,
2009; McKinney et al., 2001). This is way that bacteria like MRSA confer resistance
against antibiotics. In the absence of both mecR1/mecI and blaR1/blaI, the mecA will be
always turned on, and so the majority of the cell wall proteins synthesized will be PBP2a,
and not the normal PBP.
When the bacterium senses the surrounding environment contains toxic levels of
antibiotics, its transmembrane sensors, mecR1/blaR1, undergo a conformational change,
which is followed by autoproteolytic cleavage of the n-terminal of the cytoplasmic
domain of the transmembrane sensors. This activates the cytoplasmic peptidases, which
degrade the repressor proteins of the blaZ/mecA genes, and begins the transcription of
their respective proteins (Ender et al., 2009).
The minimum inhibitory concentrations (MIC) of antibiotics are MRSA-strain
specific. The MICs of antibiotics of two strains of MRSA can be close to one another or
have a large difference. MICs for an antibiotic like oxacillin can start as low as 1 µg/ml to
as high as values greater than 500 µg/ml (Ender et al., 2009). At this point the MICs are
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not clinically practical and the strain is therefore considered resistant to antibiotics.
Experiments have also shown that there are other genomic factors, collectively known as
fem/aux factors, that work together with the mecA gene that confers antibiotic resistance
to MRSA. These include genes that are involved in the synthesis of the precursors needed
in the formation bacterial cell wall such as teichoic acid synthesis (Ender et al., 2009).
The cell wall of MRSA and other Gram-positive bacteria is made up of
peptidoglycan macromolecules that are cross-linked to each other. These molecules
provide the necessary strength and stability, which helps in maintaining the shape of the
bacteria, and protect the bacteria from osmotic influences of the environment (Public
Health in the 21st Century: MRSA (Methicillin Resistant Staphylococcus aureus)
Infections and Treatment, 2010). Peptidoglycans are the building blocks of bacterial cell
walls and are made up of alternating chains of N-acetylglucosamine and Nacetylmuramic acid residues connected by peptide bridges (Public Health in the 21st
Century: MRSA (Methicillin Resistant Staphylococcus aureus) Infections and Treatment,
2010).
The synthesis of peptidoglycans involves three stages. The first stage takes place
in the cytoplasm and involves taking a UDP-linked N-acetylmuramic acid molecule and
sequentially adding amino acids. During the second stage, the sugar residue is transferred
to bactoprenol, a lipid carrier. The lipid carrier transports the sugar residue across the
cytoplasmic membrane. At this point N-acetylglucosamine residues will be added. In the
third stage, which takes place on the outer surface of the plasma membrane,
transglycosyation occurs, where polysaccharide chains are added to the existing chain
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(Public Health in the 21st Century: MRSA (Methicillin Resistant Staphylococcus aureus)
Infections and Treatment, 2010).
Treatments
Common Treatments
Bacterial infections are mainly treated by antibiotics. Bacterial species can differ
in terms of their overall structure and metabolic process, which creates a need to develop
different kinds of antibiotics to counter specific strains of bacteria. There are at least 11
different classes of antibiotics, each with its own sub-classes and unique members (Table
1). These classes include aminoglycosides, β-lactams, glycopeptides, lipopeptide,
macrolide, oxazolidinone, quinolone, and tetracycline (Bush, 2012). Each class has a
specific mechanism of action. The β-lactams, glycopeptide, lipopeptide, and colistin
(polymixin E) target the cell membranes of the bacteria. Aminoglycosides, macrolides,
ketolides, tetracycline, oxazolidinone, and streptogramins block protein synthesis.
Quinolone and sulfa drugs mainly affect DNA and replication (Hauser, 2013). But the list
from table 1 is not all inconclusive. There are currently many other antibiotics available
for clinical use, and many others that are in the clinical trial phase.
Vancomycin. Vancomycin is one of the most important antibiotics used to treat
Gram-positive infections like MRSA. Vancomycin is a tricyclic glycopeptide with a large
and a complex structure that works mainly by inhibiting the formation of the bacterial
cell wall (Figure 2; McNamara & Steckelberg, 2005). Vancomycin halts the production
of peptidoglycans, which form the basis of the cell wall of bacteria and binds to the Dalanyl- D-alanine terminal of the cell wall subunits (McNamara & Steckelberg, 2005).
Other drugs such as penicillins and cephalosporins can also inhibit the production of
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Table 1: Classes and sub-classes of different antibiotics

Reprinted from Current Opinion in Pharmacology, Vol 12, Karen Bush, Improving
known classes of antibiotics: an optimistic approach for the future, 527-534, Copyright
(2012), with permission from Elsevier.

Figure 2: The structure of Vancomycin. From the National Library of Medicine, accessed
November 30, 2016, at
http://www.nlm.nih.gov/pubs/techbull/ma00/ma00_chemid_fig8.html
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bacterial cell wall. These drugs usually disrupt the process of cell wall formation wall in
similar stages and sometimes result in cross-resistance of antibiotics, where the resistance
against one type of drug can allow an organism to be resistant to a different type of drug.
Vancomycin is not usually faced with problems of cross-resistance since many of the
other antibiotics affect the cell wall formation process at a much different stage.
Vancomycin can be used to treat the majority of Gram-positive bacteria; however,
vancomycin is almost useless against Gram-negative bacteria. The cell wall composition
of Gram-negative bacteria is slightly different from that of Gram-positive bacteria like
Staphylococci species (McNamara & Steckelberg, 2005). The cell walls of Gramnegative bacteria are thinner and have slightly different amino acid linkers than Grampositive bacteria.
Vancomycin doses are usually administered intravenously to treat systemic or
orthopedic infections. This is because the absorption of vancomycin in the
gastrointestinal tract is low, and most of the drug will pass through unchanged. Oral
doses are mainly used for infections that are in the gastrointestinal tract such as colitis
caused by Gram-positive bacteria such as Clostridium difficile. Once in the blood stream,
vancomycin is mainly excreted through renal glomerular filtration. The liver metabolizes
only a small fraction of the drug (McNamara & Steckelberg, 2005).
Although drug-resistance continues to be a problem with many antibiotics,
vancomycin is still considered the first-line of attack against invasive MRSA infections.
Vancomycin was developed over 50 years ago, and is still one of the strongest drugs used
against these infections (Public Health in the 21st Century: MRSA (Methicillin Resistant
Staphylococcus aureus) Infections and Treatment, 2010). Over the years vancomycin has
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been used for various conditions including endocarditis, pneumonia, and wound
infections. The cure rates for these conditions are 63%, 75%, and 90%, respectively
(Public Health in the 21st Century: MRSA (Methicillin Resistant Staphylococcus aureus)
Infections and Treatment, 2010). But vancomycin still faces challenges in some aspects
such as the treatment of lung infections because of the poor penetration rate. Also, some
strains of bacteria including MRSA have been reported to develop resistance against
vancomycin.
Vancomycin faces additional criticism from some of its adverse reactions that
some patients develop from its use. There have been reports for nephrotoxicity when
treatments are combined with aminoglycoside agents. Another adverse reaction seen in
patients taking vancomycin is “Red man syndrome”, which is caused by rapid infusion of
vancomycin leading to a reddish itchy rash on the upper trunk, neck and face as a result
of histamine release (McNamara & Steckelberg, 2005).
Quinupristin and dalfopristin. Quinupristin and dalfopristin are antibiotics that
are members of the class streptogramins. These antibiotics, which are administered
intravenously, became available for use in the United States in 1999 (Hauser, 2013).
Individually, the drugs have moderate antibacterial activity but are much more effective
when used together. These antibiotics inhibit protein synthesis in bacteria by binding to
the large (50S) subunit of the bacterial ribosome. Dalfopristin causes a conformational
change in the ribosome, which allows the binding of quinupristin (Hauser, 2013). Even
though quinupristin and dalfopristin have shown great potency against MRSA, there have
also been numerous cases of resistance against these antibiotics. Resistance against
quinupristin and dalfopristin have been due to conformational modification of the
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ribosome, which prevents the binding of streptogramins; as a result, there have been
reported cross-resistance with drugs such as macrolides and clindamycin because of
having similar binding regions (Hauser, 2013). Enzymatic degradation of the drugs and
efflux pumps are other factors that could lead to drug resistance (Hauser, 2013).
Daptomycin. Another option that can be used to treat MRSA infections is
daptomycin. Daptomycin is a cyclic lipopeptide consisting of 13 amino acids with a
decanoyl side chain that has been used to treat complicated skin and soft tissue infections
(cSSTIs) (Figure 3) (Public Health in the 21st Century: MRSA (Methicillin Resistant
Staphylococcus aureus) Infections and Treatment, 2010). Daptomycin is derived from
Streptomyces roseosporus as a fermentation product. Studies have shown that
daptomycin is as effective as vancomycin in treating MRSA related bacteremia and
endocarditis. Daptomycin is also as effective against Methicillin-Sensitive
Staphylococcus aureus (MSSA). Its high potency and rapid bactericidal activity,
especially against S. aureus, suggests daptomycin can be a better alternative in patients at
risk of serious complications of infection such as those on dialysis who are suffering from
blood stream infections caused by strains of S. aureus (Public Health in the 21st Century:
MRSA (Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 2010).
There is a low risk associated with the development of spontaneous mutational resistance
against daptomycin. This compounded with its ability to not develop cross-resistance
with other known classes of antibiotics provides an excellent alternative to treating S.
aureus related infections, including both resistant and non-resistant groups since there
have been cases where patients develop severe complications as a result of vancomycin
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Figure 3: Daptomycin Structure. Reprinted from Chemistry & Biology, Vol 11, Jason
Micklefield, Daptomycin Structure and Mechanism of Action Revealed, 887-888,
Copyright (2004), with permission from Elsevier.
doses when the bacteria is MSSA and not MRSA (Public Health in the 21st Century:
MRSA (Methicillin Resistant Staphylococcus aureus) Infections and Treatment, 2010).
Linezolid. A synthetic oxazolidone that binds to the bacterial 23S ribosomal RNA
of the 50S ribosomal subunit, linezolid, inhibits protein synthesis (Figure 4). Linezolid
has shown success against S. aureus infections as well as other Gram-positive bacteria.
The efficacy of linezolid has been shown to be similar to vancomycin. Compared to
vancomycin, there have been fewer reports of resistance, which may be due to its lower
usage. Failed treatments when using linezolid are usually caused by deep infections and
failures to drain abscesses (Public Health in the 21st Century: MRSA (Methicillin
Resistant Staphylococcus aureus) Infections and Treatment, 2010).
Proposed Alternative Treatment Methods
Duabanga grandiflora on MRSA biofilms. Many factors allow bacterial cells to
become resistant to antibiotics. One such factor is the ability of the bacterial cells to grow
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Figure 4: Structure of linezolid. Reprinted from Tuberculosis, Vol 88, Linezolid, 122125, Copyright (2008), with permission from Elsevier.
in biofilms. Biofilms significantly increase the resistance of bacteria to antibiotics by
protecting bacteria from any changes in their immediate environment including the
introduction of any potential antimicrobial agents. Studies have shown that biofilms
created by immobile organisms, such as MRSA, are physiologically different from those
of mobile organisms like planktons, which also allow for a greater survival rate within
the infected hosts. Also, these two groups of organisms have different modes of growth
(Santiago, Kuan-Hon, Hwei-San, & Kang Nee, 2015). This difference contributes to their
resistance towards antibiotics. Therefore, treatments for infections involving biofilmproducing bacteria like MRSA are much more difficult to create, which could lead to
chronic device-related infections (infections associated with surgically implanted medical
devices) (Santiago et al., 2015).
MRSA’s ability to form biofilms is one of the features that have allowed this
microbe’s increased occurrence as a nosocomial infection whose treatments are made
difficult by other virulence factors such as the PBP2a protein. Studies have shown that
PBP2a is involved in the formation of biofilms in MRSA (Santiago et al., 2015). One
hypothesis suggests that PBP2a facilitates interactions between cells in the development
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of biofilms (Santiago et al., 2015). Therefore, plausible approaches in developing new
treatments against MRSA infections is through the development of drugs that disrupt any
of the steps involved in biofilm production, or interfere with the expression of PBP2a
proteins which would eventually affect biofilm production.
Duabanga is a genus in the plant kingdom originally placed in the Sonneratiaceae
family. Presently, Duabanga is classified under the subfamily Duabangoideae of the
family Lythraceae. Duabanga is indigenous to Southeast Asia (Malik et al., 2016).
Duabanga consists of three main species, Duabanga grandiflora, Duabanga moluccana,
and Duabanga taylorii Jayaweera. In some parts of Southeast Asia including Malaysia,
the three species have other names used to identify them, Berembang Bukit, Megawasih,
and Pedada Bukit, respectively (Malik et al., 2016).
D. grandiflora trees, the subject of this section, which grow up to 30m high, are
commonly found along valleys and streams in tropical evergreen forests. These trees, and
especially its leaves, have been shown to possess medicinal properties. The leaves help
stimulate the production of type II collagen, which helps heal inflammation and slow the
aging process of the skin. The leaf extracts are also used to treat skin conditions including
eczema and atopic dermatitis (Malik et al., 2016; Santiago et al., 2015). Patients with
such skin conditions are generally predisposed to Staphylococcus aureus infections.
Extracts and purified fractions obtained from D. grandiflora have been shown to inhibit
bacterial growth. In addition to growth inhibition, studies have shown that these extracts
and fractions re-sensitized MRSA towards ampicillin and other antibiotics that were
previously ineffective against MRSA (Santiago et al., 2015). These extracts contain high
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concentration of phytochemicals such as tannins, phenolic compounds, flavonoids and
steroids. These phytochemicals also possess antiviral properties against human and
animal viruses.
In one study, Santiago et al. used a semi-purified fraction isolated from D.
grandiflora by sequential extraction using hexane, ethyl acetate, and ethanol. This
fraction named F-10 significantly inhibited the production of biofilms in bacterial
cultures including MRSA; hence, the results were an indication of promising anti-MRSA
activity (Santiago et al., 2015). As expected, F-10 contained tannins, flavonoids, and
steroids, among other things. Flavonoids disrupt the activity of sortase, a bacterial
enzyme known to influence the adhesive property of bacterial cell walls (Santiago et al.,
2015). This suggests that the presence of flavonoids in F-10 may explain its ability to
inhibit the production of biofilms by MRSA. This study also revealed that MRSA
cultures had a significantly lower expression of PBP2a in their biofilms when treated
with F-10 (Santiago et al., 2015). Disruption of biofilms and lower expression of PBP2a
due to D. grandiflora extract treatments may make MRSA less virulent and more
susceptible to antibiotics such as ampicillin that were previously ineffective.
Acalypha wilkesiana on PBP2a. A genus in the plant kingdom that is comprised
of about 450 different species of plants (S. W. Lim et al., 2011), Acalypha wilkesiana is a
shrub belonging to the Euphorbiaceae family, sometimes referred to as the spurge family
(S. W. Lim et al., 2011; Odoh et al., 2014; Olukunle, Adenubi, Biobaku, & Sogebi,
2015). This species is mainly found in Fiji and nearby islands in the South Pacific. Over
the years, its occurrence has spread to other parts of the world, especially the tropics of
Africa, America, and Asia. As a result, this species of plants has gathered a wide variety
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of names that people commonly use to refer to the plant. Some of these common names
are Joseph’s coat, referring to the different colors observed on its leaves, red leaf, fire
dragon, beefsteak plant and match-me-if-you-can. In Northern Nigeria, the Hausa people
named the plant “Jiwene” and “Jinwinini,” while the Yoruba people of Southern Nigeria
named the tree “aworoso” (S. W. Lim et al., 2011; Odoh et al., 2014; Olukunle et al.,
2015). In western parts of Nigeria, the aqueous leaf extract of A. wilkesiana has been
used as a short-term remedy for neonatal jaundice, whereas in the south, the extract is
mostly used for the treatment of skin infections in children (Odoh et al., 2014). A.
wilkesiana has been reported to show antimicrobial properties against a variety of
bacteria, including Staphylococcus aureus, Yersinia enterocolitica, Escherichia coli,
Salmonella typhi, Pseudomonas aeruginosa, and Klebsiella aerogenes. The effects of A.
wilkesiana on S. aureus led to further studies on antibiotic resistant strains of bacteria
such as MRSA. Extracts from the plant have also been used in the management of
hypertension, diabetes, gastrointestinal disorders, pain management and has potential
cytotoxic effects against cancerous cells.
PBP2a is one of the key factors that confer antibiotics resistance to MRSA.
Therefore, inactivating or decreasing the production of PBP2a will significantly help in
the fight against MRSA. Santiago et al. observed that purified extracts of A. wilkesiana
when used in conjunction with ampicillin, a non-effective treatment against MRSA, had
synergistic properties, which resulted in increased susceptibility of MRSA to ampicillin.
The minimum inhibitory concentration (MIC) of ampicillin needed to elicit antibacterial
activity against MRSA is not practical and cannot be used in a hospital setting since
ampicillin at such concentration would be toxic to patients, and therefore have no clinical
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application. However, when extracts from A. wilkesiana are used in combination with
ampicillin, the MIC of ampicillin drops significantly lower. This value is also lower than
the MIC of ampicillin needed to inhibit the growth of sensitive strains of Staphylococcus
aureus (Santiago et al., 2014). Using western blot analysis of the MRSA strains showed
low expression levels the PBP2a protein in those cultures treated with the purified
extracts from A. wilkesiana. Although extracts from the plant decreased the expression of
PBP2a proteins in MRSA, such extracts did not show any bactericidal properties
(Santiago et al., 2014), meaning, these extracts can make MRSA less resistant, but not
kill the bacteria. This creates the possibility of combining ampicillin and the extracts to
overcome ampicillin resistance, but at a much lower concentration than would normally
be needed.
The study conducted by Santiago et al. demonstrated the antimicrobial activity of
the extract of A. wilkesiana. Furthermore, the extract showed a synergistic relationship
between the extract, which was named 9EA-FC-B, and ampicillin in the inhibition of
PBP2a production, which also allowed the MRSA cultures to be inhibited by ampicillin.
The growth of MRSA was distinctly suppressed when both, the extract and ampicillin,
were used compared to MRSA cultures that were treated alone with either compound.
This effect was mainly observed during the exponential phase of the bacteria kinetic
growth curve (Santiago et al., 2014). The exponential phase is the greatest increase in
growth of bacteria observed in the presence of necessary nutrients. There was minimal
MRSA growth during this stage when 9EA-FC-B and ampicillin were introduced in their
environment. Changes were also observed during the lag phase of MRSA growth. This is
the stage where the bacteria begin to acclimate or adapt to changes in the environment.
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This stage was observed to take longer in MRSA cultures treated with 9EA-FC-B and
ampicillin (Santiago et al., 2014). Previous studies have shown compounds such as
corilagin and tellimagrandin I posses similar antimicrobial activities (Santiago et al.,
2014). Corilagin and tellimagrandin I are weak carbonic anhydrase inhibitors and are
present in numerous plants including Punica granatum, Myrtaceae, and Elaegnaceae.
Corilagin has also been previously isolated from A. wilkesiana, which suggests that the
active ingredient in the 9EA-FC-B extract maybe corilagin (Santiago et al., 2014).
Pongamia pinnata effect on MRSA. Pongamia pinnata is a legume that belongs
in the subfamily Papilionoideae (Scott et al., 2008; Yadav et al., 2011). P. pinnata is
commonly found in the Indian subcontinent and South-east Asia. Presently, P. pinnata
can be found in other parts of the world such as Australia, New Zealand, China, USA,
Philippines, and the humid tropical regions of the world. The tree derives its name from
the Tamil language of India (Scott et al., 2008). Other names associated with P. pinnata
are “Ponga,” “Dalkaramacha,” “Pongam,” “Punku,” “Karanj,” “Papar,” and “Kanji.” P.
pinnata is a medium-sized evergreen tree that grows easily on alluvial and coastal
environment in areas found at sea level to 1200m above sea level, and one of the most
admired city trees in India due to its glowing lime-green colors (Scott et al., 2008).
P. pinnata contains various phytochemical compounds. The most common ones
are flavonoids and fixed oils. The seeds of P. pinnata also contain two sterols, three sterol
derivatives, and one disaccharide, as well as eight fatty acids, of which three were
saturated. The leaves and stem of the tree are the major sites for flavonoids and chalcone
derivatives (Scott et al., 2008).
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A number of herbal remedies involve parts of the plant, P. pinnata. There have
been several documented reports that show that root extracts of the plant had significant
prophylactic abilities against aspirin-induced ulceration, although little success was
observed against ethanol-induced ulcerations. The root extracts helped to augment the
mucosal cells, mucosal cell glycoproteins, cell proliferation, and prevent lipid
peroxidation in the stomach walls (Scott et al., 2008).
P. pinnata has also shown promise in antibacterial activities. One notable impact
is its effect against MRSA. A study by Inala et al. showed crude extracts from P. pinnata
seeds were tested on clinically significant pathogens such as Klebsiella pneumonia,
Proteus vulgaris, Pseudomonas aeruginosa, Serratia marcescens, Micrococcus luteus,
and non-resistant strains of Staphylococcus aureus. Positive results from this study
prompted more tests to be done on MRSA (Inala et al., 2015). A phytochemical analysis
of the plant seeds showed the presence of alkaloids, tannins, saponins, steroids,
glycosides and flavonoids (Inala et al., 2015). Inala et al. isolated the flavonoid
components using adsorption column chromatography and used an agar well diffusion
assay to test the efficacy of the extracted flavonoids against MRSA strains that were still
susceptible to vancomycin, and the results were compared to MRSA strains that were
resistant to vancomycin (Inala et al., 2015). The results were similar, in which the
compounds displayed similar antibacterial capabilities against both vancomycin-resistant
and vancomycin-sensitive MRSA strains. Therefore, extracts from P. pinnata have
promising potential substitutes for antibiotics against MRSA that are no longer effective.
Curcuma longa against MRSA. A perennial tree that belongs to the
Zingiberaceae family (Reddy et al., 2012), Curcuma longa usually grows up to a height
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of 1m and can be found distributed in the tropical and subtropical regions of the world
but mainly cultivated in India and China. In India, commonly known as “Haldi,”
Malaysia, and Indonesia, there have been numerous studies on the plant due to the
economic importance in Malaysia and Indonesia. Other vernacular names associated with
C. longa are “Haridra” from the Telugu language, “Manjal” from the Malayalam and
Tamil language, and “Arisina” from the Kannada language (Reddy et al., 2012). All these
language groups are indigenous to India. C. longa is considered a sterile plant because of
its inability to produce any seeds. C. longa is used for both medicinal and food
preparation. The rhizomes of the plant are commonly used as household remedies in
Nepal (Reddy et al., 2012). There have been several claims in India that the plant can be
used to fight against biliary disorders, anorexia, coryza (an inflammation of the mucous
membrane of the nose, often caused by colds or hay fever), cough, diabetic wounds,
hepatic disorders, rheumatism and sinusitis. The plant can also be boiled, dried and
grounded to make turmeric, a bright yellow spice (Reddy et al., 2012).
Curcumin or diferuloymethane is a phenolic diketone (Sharma, Gescher, &
Steward, 2005). Curcumin has a molecular weight of 368.37 and melts at 183 degrees
Celsius. There are three isoforms of curcumin that have been identified in C. longa:
Curcumin I, Curcumin II, and Curcumin III (Figure 5). In acidic and neutral
environments as well as in cell membranes, the bis-keto form of curcumin predominates
(Figure 6). The enolate predominates in basic environments where curcumin acts as an
electron donor (Sharma et al., 2005).
Curcumin has a low rate of absorption. Pharmacokinetic studies in animals have
shown that about 40 to 85% of curcumin administered orally passed through the
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Figure 5: Isoforms of curcumin (Reddy et al., 2012).

Figure 6: Tautomerism of curcumin. The top one predominates in acidic/neutral
conditions, whereas the bottom one predominates in basic conditions. Reprinted from
European Journal of Cancer, Vol 41, R.A. Sharma, A.J. Gescher, W.P. Steward,
Curcumin: The story so far, 1955-1968, Copyright (2005), with permission from
Elsevier.
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gastrointestinal tract and remained unchanged. Most of the absorbed curcumin is rapidly
metabolized into several metabolites (Figure 7) in the intestinal mucosa and the liver
(Sharma et al., 2005). As a result, curcumin is usually formulated with bromelain to aid
in absorption (Sharma et al., 2005). Bromelain is a class of sulfhydryl-containing
proteolytic enzymes that is mainly extracted from a pineapple plant stem. Bromelain is
mostly used as an oral supplement to help in digestion, and sometimes used topically as
an anti-inflammatory agent (Baumann, 2008).
Curcumin is a pleiotropic molecule and can interact with a number of different
molecular targets, some of which are involved in inflammation. Curcumin helps in downregulating enzymes such as cyclooxygenase-2 (COX-2), lipoxygenase, inducible nitric
oxide synthase (iNOS), monocyte chemoattractant protein (MCP), migration inhibitory
proteins, mitogen-activated protein kinases (MAPK), and Janus kinases (Reddy et al.,
2012; Sharma et al., 2005). These enzymes are either involved in the production of
prostaglandins that mediate inflammation or control signals that elicit inflammatory
reactions. This also helps in inhibiting the production of inflammation-mediating
cytokines such as tumor necrosis factor-alpha (TNF-α), interleukin (IL) 1, 2, 6, 8, and 12.
The anti-inflammatory activity of curcumin has also helped in alleviating a number of
serious conditions. Conditions such as osteoarthritis, acute pancreatitis, and uveitis
involve inflammatory responses (Reddy et al., 2012; Sharma et al., 2005). Treatment
studies against these conditions using curcumin have shown great promise, and the
results are a stepping-stone in finding other non-conventional treatments.
Studies have shown that C. longa poses numerous medicinal potential. Among
these are anthelminthic and anti-cancer activities. In a model using Indian earthworms,
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Figure 7: Major Metabolites of Curcumin in Rodents and Humans. Reprinted from
European Journal of Cancer, Vol 41, R.A. Sharma, A.J. Gescher, W.P. Steward,
Curcumin: The story so far, 1955-1968, Copyright (2005), with permission from
Elsevier.
Pheretima posthuma, C. longa extracts were observed to paralyze and kill the
earthworms. These observations led to the conclusion that C. longa extracts could
potentially be used as an anthelminthic drug (Reddy et al., 2012). Also, rodents with
mammary tumors induced by N-methyl-N-nitrosourea (MNU), an alkylating agent that
interacts directly with DNA causing genomic mutations were tested with C. longa
extracts before and after tumor induction in order to test the prophylactic and therapeutic
potential of the plant (Reddy et al., 2012; Tsubura et al., 2011).
The results were analyzed on the basis of latency period of the tumor, tumor
incidence, tumor burden, tumor volume, tumor growth inhibition, histology and
hematological parameters. The results showed a more effective response in the
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prophylactic treatment compared to the therapeutic treatment, with topical doses having a
greater effect than oral doses (Reddy et al., 2012).
C. longa extracts have been observed to confer protection in the cardiovascular
system. These extracts help in lowering cholesterol and triglyceride levels, which are
associated with many cardiovascular disorders, and reduce the chances of peroxidation of
low-density lipoprotein (LDL) (Reddy et al., 2012). Lipid peroxidation is one of the
causes of oxidative stress in cells due to the production of free lipid radicals, damaging
the cell membranes. Other cardiovascular effects of C. longa include inhibition of platelet
aggregation, possibly through the inhibition of thromboxane synthesis (Reddy et al.,
2012).
The aging process of cells is influenced by a number of factors, including lipid
peroxidation that significantly damages cells, lipofuscin concentration and accumulation
in neurons, and the activities of enzymes such as superoxide dismutase (SOD),
glutathione peroxidase (GPx), and the Na+, K+ pump (Reddy et al., 2012). The influence
of C. longa extracts on aging was tested on 6 and 24 month old rats. Long-term
treatments with C. longa showed a significant drop in lipid peroxidation in the brain
regions, as well as a drop in the lipofuscin contents. There was an observed increase in
the activities of SOD, GPx, and the Na+, K+ pump in the brain regions as well (Reddy et
al., 2012). These observations are consistent with that of a young growing mouse brain,
indicating anti-aging prospects of C. longa extracts.
The antimicrobial activity associated with C. longa is an important feature.
Curcumin is the main component of C. longa that has shown antimicrobial capabilities.
Previous studies have observed positive results against pathogens, including Escherichia
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coli, Bacillus subtilis, Yersinia enterocolitica, Saccharomyces cerevisiae, Bacillus cereus,
Aspergillus niger, Penicillium notatum, and S. aureus (Su-Hyun et al., 2014). Such
successes have led to further tests on MRSA.
Su-Hyun et al. performed an experiment to see whether curcumin could reverse
MRSA’s resistance against antibiotics such as oxacillin. Su-Hyun et al. used both MRSA
and MSSA strains and tested for the presence of mecA gene, and treated both strains with
various concentrations of oxacillin alone, curcumin alone, and a combination of both.
The MSSA strains were inhibited by all treatments. MRSA was overall unaffected by the
oxacillin treatment (Su-Hyun et al., 2014). This was due to the production of PBP2a,
which helped overcome the stress caused by oxacillin. The PBP2a levels were as
expected. When treated with curcumin alone, the expression of PBP2a dropped
significantly, and even better results were observed when both oxacillin and curcumin
were used on MRSA (Figure 8) (Su-Hyun et al., 2014). This indicated a synergistic
relationship between curcumin and oxacillin, which is similar to the one between extracts
from A. wilkesiana and oxacillin (Su-Hyun et al., 2014). Curcumin lowers the expression
of PBP2a in MRSA, which allows oxacillin to render the normal PBP non-functional,
disrupting the bacterial cell wall synthesis, and killing the cell in the process. Results
from such experiments may result in creating alternative treatments against MRSA, and
may eventually provide relief against bacterial resistance to antibiotics.
Over the years researchers have created a large number of antibiotics. Some of
them are new classes of antibiotics, while others are derivatives of already existing ones.
The need to create new and improved drugs is due to resistance associated with certain
strains of bacteria, such as MRSA. However, overtime these strains develop resistance
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Figure 8: Western blotting showing PBP2a expression on different MRSA strains. CON
represents control sample, OX represents strains treated with oxacillin, and CCM
represents strains treated with curcumin. GAPDH was used as the control protein (SuHyun et al., 2014).
against newer medications, which leads further research in finding new drugs to counteract MRSA’s resistance. This also creates the need for continuous funding into research
for new drugs. Patients in critical conditions that are infected with MRSA have a much
lower chance of survival due to physicians having trouble finding the right treatment
course to administer. These are some of the problems that make the fight against MRSA
even that much harder.
The answer to these problems could lie with herbal extracts, such as curcumin.
These extracts have shown to affect the resistivity of MRSA to common antibiotics.
When the herbal extracts are augmented with antibiotics, the growth of bacteria is
inhibited. This helps to avoid the need to constantly manufacture new antibiotics. The
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millions of dollars spent in research to discover new antibiotics could be put to better use,
such as funding research in cancer or HIV. Also, physicians can be confident that any
treatment course administered will have a greater chance of success, which will give
patients a much higher chance of survival.
Although the use of herbal extracts as part of the current available treatments is
still in its infancy, it has shown great promise. The world is filled with diverse group of
plants, which would create a cheaper alternative to modern cures.
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established by CCC's Billing and Payment terms and conditions, these terms and conditions
shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described
in this License at their sole discretion, for any reason or no reason, with a full refund payable
to you. Notice of such denial will be made using the contact information provided by you.
Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage
incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
The following terms and conditions apply only to speciﬁc license types:
15. Translation: This permission is granted for non-exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional translator
must perform all translations and reproduce the content word for word preserving the
integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply as
follows: Licensing material from an Elsevier journal: All content posted to the web site must
maintain the copyright information line on the bottom of each image; A hyper-text must be
included to the Homepage of the journal from which you are licensing at
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at
http://www.elsevier.com; Central Storage: This license does not include permission for a
scanned version of the material to be stored in a central repository such as that provided by
Heron/XanEdu.
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier
homepage at http://www.elsevier.com . All content posted to the web site must maintain the
copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only to
bona ﬁde students registered on a relevant course. This permission is granted for 1 year only.
You may obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been peerreviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
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Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the ﬁnal versions of
articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to ﬁnd, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society-owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes authorincorporated changes suggested during submission, peer review and editor-author
communications.
Authors can share their accepted author manuscript:
-

-

immediately
via their non-commercial person homepage or blog
by updating a preprint in arXiv or RePEc with the accepted manuscript
via their research institute or institutional repository for internal institutional
uses or as part of an invitation-only research collaboration work-group
directly by providing copies to their students or to research collaborators for
their personal use
for private scholarly sharing as part of an invitation-only work group on
commercial sites with which Elsevier has an agreement
after the embargo period
via non-commercial hosting platforms such as their institutional repository
via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:
-

link to the formal publication via its DOI
bear a CC-BY-NC-ND license - this is easy to do
if aggregated with other manuscripts, for example in a repository or other site, be
shared in alignment with our hosting policy not be added to or enhanced in any way to
appear more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the deﬁnitive ﬁnal
record of published research that appears or will appear in the journal and embodies all
value-adding publishing activities including peer review co-ordination, copy-editing,
formatting, (if relevant) pagination and online enrichment.
Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
full-text. Millions of researchers have access to the formal publications on ScienceDirect,
and so links will help your users to ﬁnd, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are afﬁliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course packs
and courseware programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author-selected end-user
license and should contain a CrossMark logo, the end user license, and a DOI link to the
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formal publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.
18. For book authors the following clauses are applicable in addition to the above:
Authors are permitted to place a brief summary of their work online only. You are not
allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly
2000 established subscription journals that support open access publishing. Permitted third
party re-use of these open access articles is deﬁned by the author's choice of Creative
Commons user license. See our open access license policy for more information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modiﬁed in such a way as to damage the author's honour or
reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, ﬁgures) has appeared in our publication
with credit or acknowledgement to another source it is the responsibility of the user to
ensure their reuse complies with the terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new
works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is not
done for commercial purposes, and that the user gives appropriate credit (with a link to the
formal publication through the relevant DOI), provides a link to the license, indicates if
changes were made and the licensor is not represented as endorsing the use made of the
work. Further, any new works must be made available on the same conditions. The full
details of the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of
the Article if it is changed or edited in any way, and provided the user gives appropriate
credit (with a link to the formal publication through the relevant DOI), provides a link to the
license, and that the licensor is not represented as endorsing the use made of the work. The
full details of the license are available at http://creativecommons.org/licenses/by-nc-nd/4.0.
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY
NC ND license requires permission from Elsevier and will be subject to a fee.
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Commercial reuse includes:
-

Associating advertising with the full text of the Article
Charging fees for document delivery or access
Article aggregation
Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.
20. Other Conditions:
v1.9
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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This Agreement between Mgayya Makullah ("You") and Elsevier ("Elsevier") consists of
your license details and the terms and conditions provided by Elsevier and Copyright
Clearance Center.
License Number

4004271263065

License date

Dec 08, 2016

Licensed Content Publisher

Elsevier

Licensed Content Publication Tuberculosis
Licensed Content Title

Linezolid

Licensed Content Author
Licensed Content Date

March 2008

Licensed Content Volume
Number

88

Licensed Content Issue
Number

2

Licensed Content Pages

4

Start Page

122

End Page

125

Type of Use

reuse in a thesis/dissertation

Intended publisher of new
work

other

Portion

figures/tables/illustrations

Number of
figures/tables/illustrations

1

Format

both print and electronic

Are you the author of this
Elsevier article?

No

Will you be translating?

No

Order reference number
Original figure numbers

Linezolid

Title of your
thesis/dissertation

Current Antibiotics and Future Herbal Extract Methods to Treat
Methicillin-Resistant Staphylococcus aureus (MRSA): Focusing on
Inhibition of Penicillin-Binding Protein 2a (PBP2a)

Expected completion date

Dec 2016

Estimated size (number of
pages)

36

Elsevier VAT number

GB 494 6272 12

Requestor Location

Mgayya Makullah
2400 Weeping Willow Dr.
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United States
Attn: Mgayya Makullah
Total

0.00 USD

Terms and Conditions

INTRODUCTION
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection
with completing this licensing transaction, you agree that the following terms and conditions
apply to this transaction (along with the Billing and Payment terms and conditions
established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your
Rightslink account and that are available at any time at http://myaccount.copyright.com).
GENERAL TERMS
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to
the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, ﬁgures) has
appeared in our publication with credit or acknowledgement to another source, permission
must also be sought from that source. If such permission is not obtained then that material
may not be included in your publication/copies. Suitable acknowledgement to the source
must be made, either as a footnote or in a reference list at the end of your publication, as
follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with
permission from Elsevier."
4. Reproduction of this material is conﬁned to the purpose and/or media for which
permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However ﬁgures and illustrations may be
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of Elsevier
Ltd. (Please contact Elsevier at permissions@elsevier.com). No modiﬁcations can be made
to any Lancet ﬁgures/tables and they must be reproduced in full.
6. If the permission fee for the requested use of our material is waived in this instance,
please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not speciﬁcally granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed
immediately upon issuance of the license at the end of the licensing process for the
transaction, provided that you have disclosed complete and accurate details of your proposed
use, no license is ﬁnally effective unless and until full payment is received from you (either
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If
full payment is not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted. Further, in the event
that you breach any of these terms and conditions or any of CCC's Billing and Payment
terms and conditions, the license is automatically revoked and shall be void as if never
granted. Use of materials as described in a revoked license, as well as any use of the
materials beyond the scope of an unrevoked license, may constitute copyright infringement
and publisher reserves the right to take any and all action to protect its copyright in the
materials.
9. Warranties: Publisher makes no representations or warranties with respect to the licensed
material.
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10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and
their respective ofﬁcers, directors, employees and agents, from and against any and all
claims arising out of your use of the licensed material other than as speciﬁcally authorized
pursuant to this license.
11. No Transfer of License: This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without publisher's written permission.
12. No Amendment Except in Writing: This license may not be amended except in awriting
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you,
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment
terms and conditions. These terms and conditions, together with CCC's Billing and Payment
terms and conditions (which are incorporated herein), comprise the entire agreement
between you and publisher (and CCC) concerning this licensing transaction. In the event of
any conﬂict between your obligations established by these terms and conditions and those
established by CCC's Billing and Payment terms and conditions, these terms and conditions
shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described
in this License at their sole discretion, for any reason or no reason, with a full refund payable
to you. Notice of such denial will be made using the contact information provided by you.
Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage
incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
The following terms and conditions apply only to speciﬁc license types:
15. Translation: This permission is granted for non-exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional translator
must perform all translations and reproduce the content word for word preserving the
integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply as
follows: Licensing material from an Elsevier journal: All content posted to the web site must
maintain the copyright information line on the bottom of each image; A hyper-text must be
included to the Homepage of the journal from which you are licensing at
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at
http://www.elsevier.com; Central Storage: This license does not include permission for a
scanned version of the material to be stored in a central repository such as that provided by
Heron/XanEdu.
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier
homepage at http://www.elsevier.com . All content posted to the web site must maintain the
copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only to
bona ﬁde students registered on a relevant course. This permission is granted for 1 year only.
You may obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been peerreviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
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Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the ﬁnal versions of
articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to ﬁnd, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society-owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes authorincorporated changes suggested during submission, peer review and editor-author
communications.
Authors can share their accepted author manuscript:
-

-

immediately
via their non-commercial person homepage or blog
by updating a preprint in arXiv or RePEc with the accepted manuscript
via their research institute or institutional repository for internal institutional
uses or as part of an invitation-only research collaboration work-group
directly by providing copies to their students or to research collaborators for
their personal use
for private scholarly sharing as part of an invitation-only work group on
commercial sites with which Elsevier has an agreement
after the embargo period
via non-commercial hosting platforms such as their institutional repository
via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:
-

link to the formal publication via its DOI
bear a CC-BY-NC-ND license - this is easy to do
if aggregated with other manuscripts, for example in a repository or other site, be
shared in alignment with our hosting policy not be added to or enhanced in any way to
appear more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the deﬁnitive ﬁnal
record of published research that appears or will appear in the journal and embodies all
value-adding publishing activities including peer review co-ordination, copy-editing,
formatting, (if relevant) pagination and online enrichment.
Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
full-text. Millions of researchers have access to the formal publications on ScienceDirect,
and so links will help your users to ﬁnd, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are afﬁliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course packs
and courseware programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author-selected end-user
license and should contain a CrossMark logo, the end user license, and a DOI link to the
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formal publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.
18. For book authors the following clauses are applicable in addition to the above:
Authors are permitted to place a brief summary of their work online only. You are not
allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly
2000 established subscription journals that support open access publishing. Permitted third
party re-use of these open access articles is deﬁned by the author's choice of Creative
Commons user license. See our open access license policy for more information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modiﬁed in such a way as to damage the author's honour or
reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, ﬁgures) has appeared in our publication
with credit or acknowledgement to another source it is the responsibility of the user to
ensure their reuse complies with the terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new
works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is not
done for commercial purposes, and that the user gives appropriate credit (with a link to the
formal publication through the relevant DOI), provides a link to the license, indicates if
changes were made and the licensor is not represented as endorsing the use made of the
work. Further, any new works must be made available on the same conditions. The full
details of the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of
the Article if it is changed or edited in any way, and provided the user gives appropriate
credit (with a link to the formal publication through the relevant DOI), provides a link to the
license, and that the licensor is not represented as endorsing the use made of the work. The
full details of the license are available at http://creativecommons.org/licenses/by-nc-nd/4.0.
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY
NC ND license requires permission from Elsevier and will be subject to a fee.
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Commercial reuse includes:
-

Associating advertising with the full text of the Article
Charging fees for document delivery or access
Article aggregation
Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.
20. Other Conditions:
v1.9
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.
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your license details and the terms and conditions provided by Elsevier and Copyright
Clearance Center.
License Number

3995700090183

License date

Nov 24, 2016

Licensed Content Publisher

Elsevier

Licensed Content Publication European Journal of Cancer
Licensed Content Title

Curcumin: The story so far

Licensed Content Author

R.A. Sharma,A.J. Gescher,W.P. Steward

Licensed Content Date

September 2005

Licensed Content Volume
Number

41

Licensed Content Issue
Number

13

Licensed Content Pages

14

Start Page

1955

End Page

1968

Type of Use

reuse in a thesis/dissertation

Intended publisher of new
work

other

Portion

figures/tables/illustrations

Number of
figures/tables/illustrations

2

Format

both print and electronic

Are you the author of this
Elsevier article?

No

Will you be translating?

No

Order reference number
Original figure numbers

Figures 1, 2

Title of your
thesis/dissertation

Current Antibiotics and Future Herbal Extract Methods to Treat
Methicillin-Resistant Staphylococcus aureus (MRSA): Focusing on
Inhibition of Penicillin-Binding Protein 2a (PBP2a)

Expected completion date

Dec 2016

Estimated size (number of
pages)

36

Elsevier VAT number

GB 494 6272 12

Requestor Location

Mgayya Makullah
2400 Weeping Willow Dr.

LYNCHBURG, VA 24501
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United States
Attn: Mgayya Makullah
Total

0.00 USD

Terms and Conditions

INTRODUCTION
1. The publisher for this copyrighted material is Elsevier. By clicking "accept" in connection
with completing this licensing transaction, you agree that the following terms and conditions
apply to this transaction (along with the Billing and Payment terms and conditions
established by Copyright Clearance Center, Inc. ("CCC"), at the time that you opened your
Rightslink account and that are available at any time at http://myaccount.copyright.com).
GENERAL TERMS
2. Elsevier hereby grants you permission to reproduce the aforementioned material subject to
the terms and conditions indicated.
3. Acknowledgement: If any part of the material to be used (for example, ﬁgures) has
appeared in our publication with credit or acknowledgement to another source, permission
must also be sought from that source. If such permission is not obtained then that material
may not be included in your publication/copies. Suitable acknowledgement to the source
must be made, either as a footnote or in a reference list at the end of your publication, as
follows:
"Reprinted from Publication title, Vol /edition number, Author(s), Title of article / title of
chapter, Pages No., Copyright (Year), with permission from Elsevier [OR APPLICABLE
SOCIETY COPYRIGHT OWNER]." Also Lancet special credit - "Reprinted from The
Lancet, Vol. number, Author(s), Title of article, Pages No., Copyright (Year), with
permission from Elsevier."
4. Reproduction of this material is conﬁned to the purpose and/or media for which
permission is hereby given.
5. Altering/Modifying Material: Not Permitted. However ﬁgures and illustrations may be
altered/adapted minimally to serve your work. Any other abbreviations, additions, deletions
and/or any other alterations shall be made only with prior written authorization of Elsevier
Ltd. (Please contact Elsevier at permissions@elsevier.com)
6. If the permission fee for the requested use of our material is waived in this instance,
please be advised that your future requests for Elsevier materials may attract a fee.
7. Reservation of Rights: Publisher reserves all rights not speciﬁcally granted in the
combination of (i) the license details provided by you and accepted in the course of this
licensing transaction, (ii) these terms and conditions and (iii) CCC's Billing and Payment
terms and conditions.
8. License Contingent Upon Payment: While you may exercise the rights licensed
immediately upon issuance of the license at the end of the licensing process for the
transaction, provided that you have disclosed complete and accurate details of your proposed
use, no license is ﬁnally effective unless and until full payment is received from you (either
by publisher or by CCC) as provided in CCC's Billing and Payment terms and conditions. If
full payment is not received on a timely basis, then any license preliminarily granted shall be
deemed automatically revoked and shall be void as if never granted. Further, in the event
that you breach any of these terms and conditions or any of CCC's Billing and Payment
terms and conditions, the license is automatically revoked and shall be void as if never
granted. Use of materials as described in a revoked license, as well as any use of the
materials beyond the scope of an unrevoked license, may constitute copyright infringement
and publisher reserves the right to take any and all action to protect its copyright in the
materials.
9. Warranties: Publisher makes no representations or warranties with respect to the licensed
material.
10. Indemnity: You hereby indemnify and agree to hold harmless publisher and CCC, and
their respective ofﬁcers, directors, employees and agents, from and against any and all
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claims arising out of your use of the licensed material other than as speciﬁcally authorized
pursuant to this license.
11. No Transfer of License: This license is personal to you and may not be sublicensed,
assigned, or transferred by you to any other person without publisher's written permission.
12. No Amendment Except in Writing: This license may not be amended except in awriting
signed by both parties (or, in the case of publisher, by CCC on publisher's behalf).
13. Objection to Contrary Terms: Publisher hereby objects to any terms contained in any
purchase order, acknowledgment, check endorsement or other writing prepared by you,
which terms are inconsistent with these terms and conditions or CCC's Billing and Payment
terms and conditions. These terms and conditions, together with CCC's Billing and Payment
terms and conditions (which are incorporated herein), comprise the entire agreement
between you and publisher (and CCC) concerning this licensing transaction. In the event of
any conﬂict between your obligations established by these terms and conditions and those
established by CCC's Billing and Payment terms and conditions, these terms and conditions
shall control.
14. Revocation: Elsevier or Copyright Clearance Center may deny the permissions described
in this License at their sole discretion, for any reason or no reason, with a full refund payable
to you. Notice of such denial will be made using the contact information provided by you.
Failure to receive such notice will not alter or invalidate the denial. In no event will Elsevier
or Copyright Clearance Center be responsible or liable for any costs, expenses or damage
incurred by you as a result of a denial of your permission request, other than a refund of the
amount(s) paid by you to Elsevier and/or Copyright Clearance Center for denied
permissions.
LIMITED LICENSE
The following terms and conditions apply only to speciﬁc license types:
15. Translation: This permission is granted for non-exclusive world English rights only
unless your license was granted for translation rights. If you licensed translation rights you
may only translate this content into the languages you requested. A professional translator
must perform all translations and reproduce the content word for word preserving the
integrity of the article.
16. Posting licensed content on any Website: The following terms and conditions apply as
follows: Licensing material from an Elsevier journal: All content posted to the web site must
maintain the copyright information line on the bottom of each image; A hyper-text must be
included to the Homepage of the journal from which you are licensing at
http://www.sciencedirect.com/science/journal/xxxxx or the Elsevier homepage for books at
http://www.elsevier.com; Central Storage: This license does not include permission for a
scanned version of the material to be stored in a central repository such as that provided by
Heron/XanEdu.
Licensing material from an Elsevier book: A hyper-text link must be included to the Elsevier
homepage at http://www.elsevier.com . All content posted to the web site must maintain the
copyright information line on the bottom of each image.
Posting licensed content on Electronic reserve: In addition to the above the following
clauses are applicable: The web site must be password-protected and made available only to
bona ﬁde students registered on a relevant course. This permission is granted for 1 year only.
You may obtain a new license for future website posting.
17. For journal authors: the following clauses are applicable in addition to the above:
Preprints:
A preprint is an author's own write-up of research results and analysis, it has not been peerreviewed, nor has it had any other value added to it by a publisher (such as formatting,
copyright, technical enhancement etc.).
Authors can share their preprints anywhere at any time. Preprints should not be added to or
enhanced in any way in order to appear more like, or to substitute for, the ﬁnal versions of
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articles however authors can update their preprints on arXiv or RePEc with their Accepted
Author Manuscript (see below).
If accepted for publication, we encourage authors to link from the preprint to their formal
publication via its DOI. Millions of researchers have access to the formal publications on
ScienceDirect, and so links will help users to ﬁnd, access, cite and use the best available
version. Please note that Cell Press, The Lancet and some society-owned have different
preprint policies. Information on these policies is available on the journal homepage.
Accepted Author Manuscripts: An accepted author manuscript is the manuscript of an
article that has been accepted for publication and which typically includes authorincorporated changes suggested during submission, peer review and editor-author
communications.
Authors can share their accepted author manuscript:
-

-

immediately
via their non-commercial person homepage or blog
by updating a preprint in arXiv or RePEc with the accepted manuscript
via their research institute or institutional repository for internal institutional
uses or as part of an invitation-only research collaboration work-group
directly by providing copies to their students or to research collaborators for
their personal use
for private scholarly sharing as part of an invitation-only work group on
commercial sites with which Elsevier has an agreement
after the embargo period
via non-commercial hosting platforms such as their institutional repository
via commercial sites with which Elsevier has an agreement

In all cases accepted manuscripts should:
-

link to the formal publication via its DOI
bear a CC-BY-NC-ND license - this is easy to do
if aggregated with other manuscripts, for example in a repository or other site, be
shared in alignment with our hosting policy not be added to or enhanced in any way to
appear more like, or to substitute for, the published journal article.

Published journal article (JPA): A published journal article (PJA) is the deﬁnitive ﬁnal
record of published research that appears or will appear in the journal and embodies all
value-adding publishing activities including peer review co-ordination, copy-editing,
formatting, (if relevant) pagination and online enrichment.
Policies for sharing publishing journal articles differ for subscription and gold open access
articles:
Subscription Articles: If you are an author, please share a link to your article rather than the
full-text. Millions of researchers have access to the formal publications on ScienceDirect,
and so links will help your users to ﬁnd, access, cite, and use the best available version.
Theses and dissertations which contain embedded PJAs as part of the formal submission can
be posted publicly by the awarding institution with DOI links back to the formal
publications on ScienceDirect.
If you are afﬁliated with a library that subscribes to ScienceDirect you have additional
private sharing rights for others' research accessed under that agreement. This includes use
for classroom teaching and internal training at the institution (including use in course packs
and courseware programs), and inclusion of the article for grant funding purposes.
Gold Open Access Articles: May be shared according to the author-selected end-user
license and should contain a CrossMark logo, the end user license, and a DOI link to the
formal publication on ScienceDirect.
Please refer to Elsevier's posting policy for further information.
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18. For book authors the following clauses are applicable in addition to the above:
Authors are permitted to place a brief summary of their work online only. You are not
allowed to download and post the published electronic version of your chapter, nor may you
scan the printed edition to create an electronic version. Posting to a repository: Authors are
permitted to post a summary of their chapter only in their institution's repository.
19. Thesis/Dissertation: If your license is for use in a thesis/dissertation your thesis may be
submitted to your institution in either print or electronic form. Should your thesis be
published commercially, please reapply for permission. These requirements include
permission for the Library and Archives of Canada to supply single copies, on demand, of
the complete thesis and include permission for Proquest/UMI to supply single copies, on
demand, of the complete thesis. Should your thesis be published commercially, please
reapply for permission. Theses and dissertations which contain embedded PJAs as part of
the formal submission can be posted publicly by the awarding institution with DOI links
back to the formal publications on ScienceDirect.
Elsevier Open Access Terms and Conditions
You can publish open access with Elsevier in hundreds of open access journals or in nearly
2000 established subscription journals that support open access publishing. Permitted third
party re-use of these open access articles is deﬁned by the author's choice of Creative
Commons user license. See our open access license policy for more information.
Terms & Conditions applicable to all Open Access articles published with Elsevier:
Any reuse of the article must not represent the author as endorsing the adaptation of the
article nor should the article be modiﬁed in such a way as to damage the author's honour or
reputation. If any changes have been made, such changes must be clearly indicated.
The author(s) must be appropriately credited and we ask that you include the end user
license and a DOI link to the formal publication on ScienceDirect.
If any part of the material to be used (for example, ﬁgures) has appeared in our publication
with credit or acknowledgement to another source it is the responsibility of the user to
ensure their reuse complies with the terms and conditions determined by the rights holder.
Additional Terms & Conditions applicable to each Creative Commons user license:
CC BY: The CC-BY license allows users to copy, to create extracts, abstracts and new
works from the Article, to alter and revise the Article and to make commercial use of the
Article (including reuse and/or resale of the Article by commercial entities), provided the
user gives appropriate credit (with a link to the formal publication through the relevant
DOI), provides a link to the license, indicates if changes were made and the licensor is not
represented as endorsing the use made of the work. The full details of the license are
available at http://creativecommons.org/licenses/by/4.0.
CC BY NC SA: The CC BY-NC-SA license allows users to copy, to create extracts,
abstracts and new works from the Article, to alter and revise the Article, provided this is not
done for commercial purposes, and that the user gives appropriate credit (with a link to the
formal publication through the relevant DOI), provides a link to the license, indicates if
changes were made and the licensor is not represented as endorsing the use made of the
work. Further, any new works must be made available on the same conditions. The full
details of the license are available at http://creativecommons.org/licenses/by-nc-sa/4.0.
CC BY NC ND: The CC BY-NC-ND license allows users to copy and distribute the Article,
provided this is not done for commercial purposes and further does not permit distribution of
the Article if it is changed or edited in any way, and provided the user gives appropriate
credit (with a link to the formal publication through the relevant DOI), provides a link to the
license, and that the licensor is not represented as endorsing the use made of the work. The
full details of the license are available at http://creativecommons.org/licenses/by-nc-nd/4.0.
Any commercial reuse of Open Access articles published with a CC BY NC SA or CC BY
NC ND license requires permission from Elsevier and will be subject to a fee.
Commercial reuse includes:
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Associating advertising with the full text of the Article
Charging fees for document delivery or access
Article aggregation
Systematic distribution via e-mail lists or share buttons

Posting or linking by commercial companies for use by customers of those companies.
20. Other Conditions:
v1.8
Questions? customercare@copyright.com or +1-855-239-3415 (toll free in the US) or
+1-978-646-2777.

https://s100.copyright.com/AppDispatchServlet

6/6

